Login to Your Account



Antidepressant GLYX-13 Shows Promise in Phase IIa

By Marie Powers
Staff Writer

Friday, December 7, 2012
Privately held Naurex Inc. posted impressive Phase IIa results for lead antidepressant compound, GLYX-13, a partial agonist of the N-Methyl-D-Aspartate (NMDA) receptor, showing statistically significant reductions in depression scores in patients who had failed treatment with one or more antidepressant agents.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription